Rethinking clinical trials for cytostatic drugs (original) (raw)

• Nemunaitis, J. et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res. 4, 1101–1109 (1998).
  CAS PubMed Google Scholar
• Ravdin, P. et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J. Clin. Oncol. 13, 2879–2885 (1995).
  Article CAS Google Scholar
• ten Bokkel Huinink, W. W. et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15, 2183–2193 (1997).
  Article CAS Google Scholar
• Burris, H. A. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403–2413 (1997).
  Article CAS Google Scholar
• Van den Abbeele, A., & Badawi, R. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur. J. Cancer 38, 60–65 (2002).
  Article Google Scholar
• Drevs, J. et al. Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in two clinical phase I trials. Am. Soc. Clin. Oncol. A337 (2002).
• Slamon, D. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
  Article CAS Google Scholar
• Mouridsen H. et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21, 2101–2109 (2003).
  Article CAS Google Scholar
• The ICON group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360, 505–515 (2002).
• Sirotnak, F. et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase1. Clin. Cancer Res. 6, 4885–4892 (2000).
  CAS PubMed Google Scholar
• Pollack, V. A. et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291, 739–748 (1999).
  CAS PubMed Google Scholar
• Albain, K. et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (swog–8814). Am. Soc. Clin. Oncol. A143 (2002).
• Garratt, A. et al. ErbB2 pathways in heart and neural disease. Trends Cardiovasc. Med. 13, 80–86 (2003).
  Article CAS Google Scholar
• A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy naive patients with advanced non-small-cell lung cancer (INTACT 1) Ann. Onc. 13 (suppl. 5), 2 (2002)
• Kuenen, B. et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J. Clin. Oncol. 20, 1657–1667 (2002).
  Article CAS Google Scholar
• Demetri, G. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472–479 (2002).
  Article CAS Google Scholar
• Heinrich, M. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708–710 (2003).
  Article CAS Google Scholar
• Rubin, B. et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with dermatofibrosarcoma protuberans. J. Clin. Oncol. 20, 3586–3591 (2002).
  Article CAS Google Scholar
• Betensky, R. et al. Influence of unrecognised molecular heterogeneity on randomised clinical trials. J. Clin. Oncol. 20, 2495–2499 (2002).
  Article Google Scholar
• Van de Vijver, M. J. et al. A gene expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
  Article CAS Google Scholar
• Rosner, G. et al. Randomized discontinuation design: application to cytostatic antineoplastic agents. J. Clin. Oncol. 20, 4478–4484 (2002).
  Article CAS Google Scholar
• Johnson, J. et al. End points and United States Food and Drug Administration of Oncology Drugs. J. Clin. Oncol. 21, 1404–1411 (2003).
  Article Google Scholar
• Saltz, L. B. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 343, 905–914 (2000).
  Article CAS Google Scholar
• Van Cutsem, E. et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 19, 4093–4096 (2001).
  Article Google Scholar
• Berenson, J. Z. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin. Oncol. 28, 25–34 (2001).
  Article CAS Google Scholar
• Menssen, D. H. et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J. Clin. Oncol. 20, 2353–2359 (2002).
  Article CAS Google Scholar
• Albanell, J. et al. pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20, 110–124 (2002).
  Article CAS Google Scholar
• Lockhart, A. et al. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res. 9, 586–593 (2003).
  CAS PubMed Google Scholar
• Schiller, J. et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346, 92–98 (2002).
  Article CAS Google Scholar
• Hurwitz, H. I. et al. Antiangiogenic therapy plus IFL improves survival for patients with metastatic colorectal cancer. Am. Soc. Clin. Oncol. A3646 (2003).